Comparison between the effects of low-dose spironolactone plus metformin and metformin alone on hormonal and biochemical parameters of insulin resistance in women with polycystic ovary syndrome
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20262076Keywords:
Fetal distress, Hypertension in pregnancy, StillbirthsAbstract
Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in reproductive-age women, characterized by insulin resistance and hyperandrogenism. Metformin improves insulin sensitivity, while spironolactone has antiandrogenic effects. Evidence regarding the short-term benefit of combining low-dose spironolactone with metformin remains inconclusive, particularly in South Asian populations. This study aimed to compare the effects of low-dose spironolactone plus metformin versus metformin alone on hormonal and biochemical parameters of insulin resistance in women with PCOS.
Methods: This randomized controlled trial was conducted at Bangabandhu Sheikh Mujib Medical University, Dhaka, from July 2023 to June 2024. Ninety women aged 18-40 years with PCOS (Rotterdam criteria), BMI 18-30 kg/m2, and HOMA-IR>2 were randomized to receive either spironolactone (50 mg/day) plus metformin (1500 mg/day) or metformin alone (1500 mg/day) for 12 weeks. Hormonal and metabolic parameters were measured at baseline and post-treatment.
Results: Both groups showed significant improvements in BMI, waist circumference, serum LH, FSH, LH/FSH ratio, free testosterone, fasting glucose, fasting insulin, and HOMA-IR (p<0.05). The combination group demonstrated numerically greater reductions in LH (3.02 versus 1.92 µIU/ml), free testosterone (0.33 versus 0.22 pg/ml), and HOMA-IR (1.37 versus 1.11); however, none of the between-group differences were statistically significant (p>0.05).
Conclusions: Both low-dose spironolactone plus metformin and metformin alone significantly improve hormonal and insulin resistance parameters in women with PCOS. However, the addition of spironolactone does not provide a significant short-term advantage over metformin alone.
References
Leelaphiwat S, Wongwananuruk T, Rattanachaiyanont M et al. Prevalence of polycystic ovary syndrome in Thai women: a community-based study. J Obstet Gynecol Res. 2022;48(3):789-97.
Li R, Zhang Q, Yang D, Li S, Lu S, Wu X, et al. Prevalence of polycystic ovary syndrome in women in China: a large community-based study. Hum Reprod. 2013;28(9):2562-9.
Dunaif A. Insulin resistance in polycystic ovary syndrome: mechanisms and therapeutic implications. Endocr Rev. 2022;43(3):521-45.
Mazza A, Fruci B, Guzzi P, D’Orrico B, Malaguarnera R, Veltri P, et al. In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. Nutr Metab Cardiovasc Dis. 2014;24(2):132-9.
Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565-92.
Viollet B, Guigas B, Garcia NS, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci. 2022;136(12):925-48.
Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin-sensitising drugs for women with polycystic ovary syndrome, oligoamenorrhoea and subfertility. Cochrane Database Syst Rev. 2023;5(5):CD003053.
Rani N, Kumar P, Mishra AK, Sankuratri BY, Sethi S, Gelada K, et al. Efficacy of spironolactone in adult acne in polycystic ovary syndrome patients an original research. J Pharm Bioallied Sci. 2021;13(Suppl 2):S1659-63.
Long T, Zhang Y, Zeng C, Zheng S, Zhou L, Liu H. Effects of low‐dose spironolactone combined with metformin or either drug alone on insulin resistance in patients with polycystic ovary syndrome: a pilot study. Int J Endocrinol. 2022;2022(1):9927240.
Zeng H, Zhang Y, Huang S, Wu J, Ren W, Zhou L, et al. Metformin combined with spironolactone vs. metformin alone in polycystic ovary syndrome: a meta-analysis. Front Endocrinol. 2023;14:1223768.
Shefin SM, Sobhan R, Qureshi NK. Metabolic and hormonal parameters in polycystic ovary syndrome: a cross-sectional, multicenter study in Bangladesh. Bangladesh J Endocrinol Metab. 2024;3(3):102-6.
Ling J, Quan L, Liu Y, Feng S, Chen L, Zhang Y, et al. Combined liraglutide and metformin therapy in overweight or obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Diabetes Obes Metab. 2025;27(11):6139-53.
Tosi F, Zanolin ME, Garofalo S, Gremes V, Zoppini G, Moghetti P. Effect on insulin clearance of different pharmacological treatments in women with polycystic ovary syndrome: a hypothesis-generative study. J Endocrinol Invest. 2026:1-9.
Viveiros TM, Deshpande N, Karderinis I, Ma Y, Clarke S, Talaulikar V, et al. Short‐term, low‐dose spironolactone for treatment of hyperandrogenic symptoms of polycystic ovary syndrome- a systematic review. Clin Endocrinol. 2026;104(3):179-87.
Karderinis I, Ma Y, Viveiros T, Deshpande N, Watter B, Talaulikar V. Spironolactone and metformin combination therapy as a potential non-hormonal treatment for management of hyperandrogenic symptoms of polycystic ovarian syndrome. Clin Med. 2025;25(4):100461.
Garcia-Beltran C, Malpique R, Andersen MS, Bas F, Bassols J, Darendeliler F, et al. SPIOMET4HEALTH- efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a multicentre, randomised, double-blind, placebo-controlled, four-arm, parallel-group, phase II clinical trial. Trials. 2023;24(1):589.
Abdalla MA, Shah N, Deshmukh H, Sahebkar A, Östlundh L, Al-Rifai RH, et al. Impact of pharmacological interventions on biochemical hyperandrogenemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials. Arch Gynecol Obstet. 2023;307(5):1347-76.
Downloads
Published
How to Cite
Issue
Section
